Target intelligence / Profile preview

C3a anaphylatoxin chemotactic receptor (C3AR1)

Target
C3AR1
Molecular classification
G protein-coupled receptor, Receptor
01

Overview

The C3a anaphylatoxin chemotactic receptor (C3AR1), commonly known as the C3a receptor (C3aR), is a rhodopsin-like G protein-coupled receptor (GPCR) that plays a pivotal role in the innate immune system. It is primarily activated by C3a, a pro-inflammatory anaphylatoxin generated during the complement activation cascade. C3aR is widely expressed on myeloid cells (such as mast cells, macrophages, and neutrophils) as well as non-myeloid cells in the central nervous system and peripheral tissues. Upon ligand binding, C3aR triggers intracellular signaling pathways, including Galpha-i and Galpha-12/13 activation, calcium mobilization, and beta-arrestin recruitment, which mediate chemotaxis, degranulation, and cytokine production.

C3aR signaling is heavily implicated in the pathogenesis of various inflammatory, cardiovascular, and neurodegenerative diseases, including asthma, ischemic stroke, diabetic nephropathy, and neuropathic pain. While acute activation of C3aR often exacerbates tissue damage and neuroinflammation, it can also exert protective, regenerative effects during subacute or chronic recovery phases, highlighting a complex, double-edged role. Therapeutic targeting of C3aR has focused on developing small-molecule antagonists, such as SB290157 and JR14a, to mitigate pathological inflammation. However, drug development has been challenged by the pharmacological complexity of existing ligands, some of which exhibit partial agonism or signaling bias, and no C3aR-targeted therapies have successfully transitioned to clinical trials to date.

Other names
Complement component 3a receptor 1C3a receptorC3a-RC3ARAZ3BHNFAG09
02

Mechanism of action

Antagonist of the C3a receptor, blocking C3a-mediated signaling and chemotaxis; or agonist activating downstream G-protein and beta-arrestin pathways.

03

Biological functions

Signal transductionImmune responseInflammationCell migrationChemotaxisDegranulation
04

Disease associations

InflammationNeurodegenerative diseaseCardiovascular diseaseCancerOther
05

Safety considerations

Phase-specific dual roles in tissue injury and repairOff-target effects and partial agonism of existing ligandsPotential impairment of host defense against infectionsComplex signaling bias leading to unexpected functional outcomes
06

Interacting drugs

7 more in the full profile.

07

Biomarkers

C3a levelsC3AR1 expressionTRPV4 expressionPhosphorylated ERK1/2Intracellular calcium mobilization

Beyond the preview

Go deeper on C3a anaphylatoxin chemotactic receptor (C3AR1).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on C3a anaphylatoxin chemotactic receptor (C3AR1).

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call